Related Experiment Video
Updated: Dec 15, 2025
07:45
A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
Published on: June 27, 2011
13.0K
Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity
Hamid Bakherad1, Mohammad Farahmand2, Neda Setayesh2
1Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Life Sciences
|July 8, 2020
Summary
Engineered nanobodies targeting granulocyte colony-stimulating factor receptor (G-CSF-R) show improved binding affinity. These novel nanobodies hold potential for enhanced tumor imaging and therapeutic applications.
Area of Science:
- Immunology and Cancer Biology
- Biotechnology and Nanomedicine
Background:
- Granulocyte colony-stimulating factor (G-CSF) is a cytokine involved in hematopoiesis and neutrophil activation.
- G-CSF receptor (G-CSF-R) overexpression in tumors suggests its potential as a therapeutic target.
- Nanobodies offer unique advantages for developing targeted cancer therapies and imaging agents.
Purpose of the Study:
- To engineer a previously identified G-CSF-R targeting nanobody (VHH1) for enhanced binding affinity.
- To improve the therapeutic and diagnostic potential of nanobodies against G-CSF-R.
Main Methods:
- Rational design was employed to modify the complementary determining region 3 (CDR3) of the VHH1 nanobody.
- Five engineered nanobodies were generated to better mimic G-CSF interaction with its receptor.
- Binding affinity was assessed using Enzyme-linked immunosorbent assay (ELISA) on NFS60 cells.
Main Results:
- ELISA confirmed the specificity of the engineered nanobodies for G-CSF-R.
- Two engineered nanobodies, designated 1c and 5a, demonstrated dose-dependent binding to G-CSF-R on NFS60 cells.
- Nanobodies 1c and 5a exhibited higher binding potency compared to the original VHH1 nanobody.
Conclusions:
- Engineered nanobodies 1c and 5a show promising enhanced affinity for G-CSF-R.
- Further in vitro and in vivo studies are necessary to fully characterize these nanobodies.
- These novel nanobodies represent a foundation for developing advanced G-CSF-R-targeted imaging and therapeutic agents.
